Our analysis confirms that lower expression of CTTNBP2 and MCF2L is significantly correlated to worse prognostic features, including the high-risk category (CTTNBP2: p = 0.009; MCF2L: p = 2.78 × 10−10), presence of MYCN amplification (CTTNBP2: p = 0.003; MCF2L: p = 1.94 × 10−6), and advanced disease stage, specifically stage 4 according to the International Neuroblastoma Staging System (INSS) (CTTNBP2: p = 0.002; MCF2L: p = 5.37 × 10−9), (Fig. 6a). This evidence concerns the gene CTTNBP2 and neuroblastoma.